Under construction – not a live service
Sign in
Taking peoplePhase 3

CagriSema versus semaglutide for weight loss in obesity, with or without type 2 diabetes

Compares CagriSema with semaglutide for weight loss in adults with obesity.

Plain-language title generated from the registry record
Registry title: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Key facts

Where
Baja, Bekescsaba, Békéscsaba, Biatorbágy, Budapest III, Budapest VIII, Budapest XIV, Nyíregyháza, Szeged, and Szolnok, HungarySee the 12 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with obesity, with or without type 2 diabetes. It compares two doses of CagriSema with semaglutide for weight loss.

Age
18 years or older
Sex
All sexes can join (sex assigned at birth, all gender identities).
Disease stage
Obesity with BMI of 35.0 kg/m^2 or higher. People without type 2 diabetes need HbA1c below 6.5% (48 mmol/mol). People with type 2 diabetes need HbA1c below 10% (86 mmol/mol).
Earlier treatment
No GLP-1 receptor agonist or amylin analogue (or medicine with that activity) in the 6 months before screening.
Biomarker or test result
HbA1c below 6.5% (48 mmol/mol) without type 2 diabetes; below 10% (86 mmol/mol) with type 2 diabetes.

Main reasons for not taking part

  • Self-reported body weight change of more than 5% in the 90 days before screening
  • Use of a GLP-1 receptor agonist or amylin analogue in the 6 months before screening

Read by machine on 9 November 2026.

Where in Hungary

  • Eureka-Center Bt.Baja, HungaryNo longer taking part
  • Lausmed KftBaja, HungaryNo longer taking part
  • Bekes Varmegyei Koezponti KorhazBekescsaba, HungaryNo longer taking part
  • Pericardio Kft.Békéscsaba, HungaryNo longer taking part
  • Trial Pharma Kft.Békéscsaba, HungaryNo longer taking part
  • Biatros Kft.Biatorbágy, HungaryNo longer taking part
  • Obudai Egeszseguegyi Centrum Kft.Budapest III, HungaryNo longer taking part
  • Semmelweis UniversityBudapest VIII, HungaryNo longer taking part
  • Cardiogeneral Kft.Budapest XIV, HungaryNo longer taking part
  • Medifarma-98 Kft.Nyíregyháza, HungaryNo longer taking part
  • University of SzegedSzeged, HungaryNo longer taking part
  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-RendelointézetSzolnok, HungaryNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Novo Nordisk A/S
Trial code
NCT07564414EU 2025-522488-14-00
Record updated
30 September 2026
Original description
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeksRead full original descriptionShow less

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; BMI≥ 35.0 kg/m\^2; Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.

Exclusion: A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records; Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

ClinicalTrials.gov NCT07564414 · EU CTIS 2025-522488-14-00